U.S. hospitals face chemo shortage

U.S. hospitals are again confronting shortages of older, generic chemotherapy drugs that remain central to routine cancer care. Carboplatin, cisplatin, oxaliplatin and ifosfamide are among the agents under pressure, according to hospital supply trackers and oncology groups. The squeeze is hitting drugs that are off patent, sold at low prices and made in sterile injectable plants that are costly to run. Doctors and pharmacists say the result is not abstract: treatment plans get altered, doses are scheduled more tightly, and some centers prepare for allocation decisions if supply worsens. ### Which chemotherapy drugs are in shortest supply right now? ASHP said in its July 29 shortage update that carboplatin injection had “insufficient supply for usual ordering.” Its listing shows multiple manufacturers with back orders, limited supply, discontinuations or no release date for some vial sizes. Apotex discontinued carboplatin in early 2026, while other suppliers cited increased demand, shipping delays or gave no reason. (ashp.org) Drugs.com, citing reporting from The New York Times on June 26, said hospitals buying through Premier had only about two-thirds of their cisplatin orders filled and 38% of their ifosfamide orders filled. The same report said doctors were already discussing who should receive ifosfamide if supply remains constrained. ### Why are these shortages hitting older cancer drugs? The FDA says drug shortages can arise from manufacturing and quality problems, delays and discontinuations. (ashp.org) For sterile injectables, those risks are amplified because the drugs must be made in highly controlled facilities, and a problem at one plant can remove a large share of supply. FDA says it works with manufacturers once a drug is listed in its shortage database and can use early reports of local shortages to try to prevent a national shortage. (drugs.com) Matthew Christian, director of supply chain insights at U.S. Pharmacopeia, told Time that the problem had been building for some time. Time reported that hospitals were struggling to source sterile generic chemotherapy drugs because few manufacturers remain in a business with thin margins and high production complexity. ### What changes at the bedside when carboplatin is scarce? ASCO says the first step is to re-prioritize non-essential use of antineoplastic agents in limited supply. (fda.gov) If a comparable alternative exists, ASCO says the scarce drug should not be ordered. The group also recommends using the longer end of guideline dosing intervals when clinically acceptable, defaulting to the lowest therapeutically proper dose within guideline ranges, and minimizing waste through dose rounding, vial-size optimization and multi-use vials. (time.com) ASCO’s ethical guidance says shortages can leave patients and oncologists facing delays, waitlists or “suboptimal clinical options and outcomes.” The paper says severe shortages can force explicit rationing and argues that institutions need transparent, equitable allocation plans rather than ad hoc decisions by individual clinicians. ### Are hospitals already rationing cancer treatment? Dr. Andrew Shuman of the University of Michigan told The New York Times, as quoted by Drugs.com, that some clinicians were already steering scarce doses toward patients most likely to benefit. (asco.org) Dr. Lucio Gordan, president of Florida Cancer Specialists and Research Institute, said securing carboplatin, cisplatin and oxaliplatin had been “very difficult” and called the three drugs “the backbone of many cancer therapies.” (ascopubs.org) ASCO says institutions should create multidisciplinary utilization committees to monitor shortages, set internal policies and act as independent arbiters for equitable use. That guidance is already posted alongside disease-specific recommendations for practices managing shortages of platinum agents and other oncology drugs. ### What happens next for patients and providers? The FDA says patients, healthcare providers and organizations can report existing or new shortages through the agency’s drug-shortage channels, and it says local stock-outs can serve as an early warning of broader supply trouble. (drugs.com) ASHP continues to post manufacturer-by-manufacturer resupply estimates, and oncology practices are using those updates with ASCO guidance to decide whether to substitute regimens, stretch intervals or conserve remaining stock. (asco.org) (fda.gov)